Getting a handle on KRAS inhibitor resistance with hapten-mediated anti-tumor immunity.

Covalent inhibitors of oncogenic KRAS have demonstrated impressive clinical responses; however, therapeutic resistance has been commonly observed. In this issue, Zhang and colleagues demonstrate that small molecule KRAS inhibitors can generate haptenated major histocompatibility complex (MHC) class I:peptide complexes, which represent attractive targets for immune-based therapies to combat pharmacologic resistance.